Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
The long-awaited NHS 10 Year Health Plan, unveiled today by Sir Keir Starmer, has set out a bold vision for reshaping health and care in England with community and the NHS App at its core to deliver for patients.
Health…
The founder and CEO of innovation coalition the Health Tech Alliance talks prioritising patient benefit over profit and how SMEs and startups better engage with the NHS.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us